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I N T RODUC T I ON
The electrical activity of the nervous system depends 
on the precise tuning of the electrophysiological proper-
ties of neurons through various mechanisms. The inter-
action of auxiliary subunits of voltage-gated channels 
with their pore-forming -subunits provides one power-
ful means of regulating neural function by controlling 
channel expression and gating (Arikkath and Campbell, 
2003; Vacher and Trimmer, 2011). The actions of neu-
rotransmitters to modulate voltage-gated channel func-
tion through various second messenger signaling 
pathways provide another means for the more dynamic 
control of neural firing properties. We now find that the 
cAMP-dependent modulation of hyperpolarization-
activated cyclic nucleotide–regulated cation (HCN) chan-
nels undergoes a surprising form of regulation by the 
brain-specific auxiliary HCN channel subunit TRIP8b 
(Santoro et al., 2004).
HCN channels are composed of four pore-forming 
-subunits encoded by members of a small gene family 
(HCN1–4) that is part of the larger voltage-gated channel 
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superfamily (Robinson and Siegelbaum, 2003; Biel et al., 
2009). Unlike most voltage-gated channels, the HCN 
channels are nonselective cation channels that are acti-
vated by membrane hyperpolarization, resulting in the 
hyperpolarization-activated cation current, Ih. The bind-
ing of cAMP to the highly conserved HCN cytoplasmic 
C-terminal cyclic nucleotide–binding domain (CNBD) en-
hances channel opening by shifting the voltage depen-
dence of HCN channel gating to more positive potentials 
(DiFrancesco and Tortora, 1991; Wainger et al., 2001). 
This effect is sometimes associated with an increase in the 
maximal current through the population of HCN chan-
nels (Imax) at strongly hyperpolarized voltages (Craven and 
Zagotta, 2004; Shin et al., 2004). These results are consis-
tent with a model in which channel opening consists of a 
voltage-dependent activation step coupled to a voltage-in-
dependent opening step: cAMP binding enhances chan-
nel opening and shifts the voltage dependence of gating 
to more positive potentials by stabilizing the closed to open 
transition of the channel (Zhou and Siegelbaum, 2007).
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Hyperpolarization-activated cyclic nucleotide–regulated cation (HCN) channels generate the hyperpolariza-
tion-activated cation current Ih present in many neurons. These channels are directly regulated by the bind-
ing of cAMP, which both shifts the voltage dependence of HCN channel opening to more positive potentials 
and increases maximal Ih at extreme negative voltages where voltage gating is complete. Here we report that 
the HCN channel brain-specific auxiliary subunit TRIP8b produces opposing actions on these two effects of 
cAMP. In the first action, TRIP8b inhibits the effect of cAMP to shift voltage gating, decreasing both the sen-
sitivity of the channel to cAMP (K1/2) and the efficacy of cAMP (maximal voltage shift); conversely, cAMP 
binding inhibits these actions of TRIP8b. These mutually antagonistic actions are well described by a cyclic 
allosteric mechanism in which TRIP8b binding reduces the affinity of the channel for cAMP, with the affinity 
of the open state for cAMP being reduced to a greater extent than the cAMP affinity of the closed state. In a 
second apparently independent action, TRIP8b enhances the action of cAMP to increase maximal Ih. This 
latter effect cannot be explained by the cyclic allosteric model but results from a previously uncharacterized 
action of TRIP8b to reduce maximal current through the channel in the absence of cAMP. Because the bind-
ing of cAMP also antagonizes this second effect of TRIP8b, application of cAMP produces a larger increase in 
maximal Ih in the presence of TRIP8b than in its absence. These findings may provide a mechanistic explana-
tion for the wide variability in the effects of modulatory transmitters on the voltage gating and maximal am-
plitude of Ih reported for different neurons in the brain.
© 2013 Hu et al. This article is distributed under the terms of an Attribution–Noncommercial– 
Share Alike–No Mirror Sites license for the first six months after the publication date 
(see http://www.rupress.org/terms). After six months it is available under a Creative Com-
mons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described 
at http://creativecommons.org/licenses/by-nc-sa/3.0/).
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600 TRIP8b shifts mode of cAMP action on HCN channels
Here we have investigated the effects of TRIP8b on 
HCN channel function using both TRIP8b-HCN2 fu-
sion proteins and direct application of the TRIP8b core 
region to HCN2 channels in inside-out patches. Our re-
sults indicate that TRIP8b acts through an allosteric 
mechanism to decrease the affinity of the channel for 
cAMP. Moreover, we report a previously uncharacter-
ized action of TRIP8b to reduce maximal current 
through the channel in the absence of cAMP. By reversing 
this action of TRIP8b, cAMP produces an increase in 
maximal current significantly greater than that seen in 
the absence of the auxiliary subunit. Thus, TRIP8b ex-
erts opposing influences on the two major actions of 
cAMP on HCN channel function. The auxiliary subunit 
reduces the effect of cAMP to shift the voltage depen-
dence of channel gating but enhances the action of 
cAMP to increase maximal current. These effects have 
important implications for the physiological actions of 
cAMP to alter neuronal excitability.
MAT E R I A L S  AND  M E THOD S
Constructs and expression
All constructs were cloned in pGHE or pGH19 vectors, linear-
ized, and transcribed into cRNA using T7 polymerase (Mes-
sageMachine; Ambion) as described previously (Santoro et al., 
2004, 2009). cDNA clones encoding HCN2 and TRIP8b both 
correspond to the Mus musculus sequence. GFP, TRIP8b, and 
TRIP8bcore fused to HCN2 channels were created as described 
previously (Santoro et al., 2011). Site-directed mutagenesis was 
performed using either the QuikChange Mutagenesis kit (Agi-
lent Technologies) or PCR cloning. Xenopus laevis oocytes were 
injected with 30–50 nl cRNA solutions at a concentration of 
0.5–1 µg/µl.
Biochemical binding assays
The yeast two-hybrid assay and coimmunoprecipitation techniques 
used here were described in detail in a previous publication (Santoro 
et al., 2011). In brief, yeast two-hybrid assays were performed using 
the Grow’N’Glow Two-Hybrid kit (Bio 101) and yeast strain EGY48. 
Bait constructs representing the indicated HCN1 channel domains 
were cloned into vector pEG202, and prey constructs representing 
the indicated TRIP8b domains (or mutants thereof) were cloned in 
vector pJG4-5. Bait and prey plasmids were cotransformed with re-
porter plasmid pGNG1, and cells were plated onto glucose-con-
taining medium. Transformants were restreaked (in triplicate) on 
galactose+/Leu selective medium and screened for positive GFP 
expression under a UV light after 3–5 d of growth. For coimmuno-
precipitation, Xenopus oocytes were injected with 50 nl of cRNA solu-
tion each, at a concentration of 1.0 µg/µl for HCN1 channel 
constructs and 0.2 µg/µl for TRIP8b or GFP-TRIP8b fusion con-
structs. Oocytes were collected 3 d after injection, and protein 
extracts were prepared in ice-cold lysis buffer, followed by coimmu-
noprecipitation and Western blot analysis as described previously 
(Santoro et al., 2011). Primary antibodies used were anti-HCN1 (rat 
monoclonal 7C3; gift of F. Müller [Institute of Complex Systems, 
Jülich, Germany] and U.B. Kaupp [Center of Advanced European 
Studies and Research, Bonn, Germany]), anti-TRIP8b (rabbit poly-
clonal 794; Santoro et al., 2009), and anti-GFP (290; Abcam). HRP-
anti–rat conjugate (Jackson ImmunoResearch Laboratories, Inc.) or 
HRP-anti–rabbit conjugate (Cell Signaling Technology) was used as 
One puzzling aspect of the actions of modulatory 
transmitters on Ih is that the relative extent by which 
they alter maximal Ih or shift the voltage dependence 
of channel gating can vary widely among different clas-
ses of neurons. In most neurons, neurotransmitters act 
through second messenger cascades primarily to shift 
the voltage dependence of Ih gating; in some cells, how-
ever, transmitters produce substantial changes in maximal 
Ih elicited by voltage steps to extreme negative poten-
tials where voltage gating has reached completion, with or 
without an accompanying shift in voltage gating (Bobker 
and Williams, 1989; McCormick and Williamson, 1991; 
Kiehn and Harris-Warrick, 1992; Larkman and Kelly, 
1992; Erickson et al., 1993; Gasparini and DiFrancesco, 
1999; Bickmeyer et al., 2002; Schweitzer et al., 2003; 
Frère and Lüthi, 2004; Battefeld et al., 2010; Heys and 
Hasselmo, 2012).
Here we report that the binding of TRIP8b to the 
HCN2 -subunit differentially alters the two major actions 
of cAMP on HCN channel function. TRIP8b, the major 
auxiliary subunit of HCN channels in the brain, controls 
HCN channel membrane trafficking, dendritic localiza-
tion, and cAMP-dependent voltage gating (Santoro et al., 
2004, 2009, 2011; Lewis et al., 2009; Zolles et al., 2009; 
Han et al., 2011; Piskorowski et al., 2011). TRIP8b under-
goes extensive alternative splicing at its N terminus, gen-
erating at least 10 splice variants expressed in the brain 
that produce diverse effects to either enhance or suppress 
channel plasma membrane expression. However, all iso-
forms exert an identical action to inhibit the ability of 
cAMP to shift HCN channel opening to more positive po-
tentials (Santoro et al., 2009; Zolles et al., 2009), an effect 
which has been mapped to a specific interaction site. 
TRIP8b interacts with HCN channels at two distinct sites: 
an upstream site in which a conserved central core region 
of TRIP8b binds to the HCN CNBD and a downstream 
site in which the C-terminal tetratricopeptide repeat 
(TPR) domain of TRIP8b interacts with the Ser-Asn-Leu 
(SNL) tripeptide at the C terminus of the channel (Lewis 
et al., 2009; Han et al., 2011; Santoro et al., 2011). It is 
the interaction of the central core domain of TRIP8b with 
the CNBD that is responsible for the effect of the auxil-
iary subunit to antagonize the action of cAMP (Santoro 
et al., 2011).
The precise mechanism by which TRIP8b binding re-
duces the response to cAMP is controversial. In a bio-
chemical study, Han et al. (2011) have suggested that 
TRIP8b directly antagonizes the binding of cAMP by a 
competitive interaction with the ligand-binding site of 
the CNBD. In contrast Zolles et al. (2009), using an 
electrophysiological approach, reported that TRIP8b 
reduces the maximal voltage shift in response to satu-
rating concentrations of cAMP, Vmax, an effect incom-
patible with direct competition. No study to date has 
addressed whether TRIP8b binding alters the ability of 
cAMP to enhance maximal HCN channel current.
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Model fitting
The modulation of HCN2 channel opening by voltage, cAMP, 
and TRIP8b was described by a 12-state allosteric model (Fig. 6). 
Definitions of all terms are described in Fig. 6. The open proba-
bility of the channel is determined from the equation
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Solving Eqs. 1 and 2 yields the voltage shift produced by a given 
concentration of cAMP (A) in the presence of a given concentra-
tion of TRIP8b (T)
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The relationship in Eq. 3 for V1/2 as a function of cAMP concen-
tration and TRIP8b concentration was used in the model fitting 
of Fig. 7.
At extreme negative voltages in the absence of cAMP, the maxi-
mal open probability is given by
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The current reduction caused by the TRIP8bcore polypeptide can 
be described from the following relationship:
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Fitting of the current reduction as a function of TRIP8bcore pep-
tide concentration (data in Fig. 4 B) by the model yields the fol-
lowing values: KC
T  = 0.34 µM and KO
T  = 1.90 µM. The fitting of 
the model was conducted in MATLAB with the fitnlm function.
Online supplemental material
Detailed derivations and fitting procedures are provided in the 
supplemental text. Online supplemental material is available at 
http://www.jgp.org/cgi/content/full/jgp.201311013/DC1.
a secondary antibody. The protein bands were visualized by chemilu-
minescence using SuperSignal reagent (Thermo Fisher Scientific).
Affinity purification of TRIP8bcore peptide
A cDNA fragment encoding residues 223–303 (TRIP8bcore) of 
TRIP8b (1a-4) was cloned into vector pET52b (EMD Millipore) 
downstream of a Strep (II) tag sequence. The plasmid was trans-
formed into Escherichia coli BL21 Rosetta strain (EMD Millipore) 
under ampicillin selection. Cells were grown at 37°C in Luria broth 
to 0.6 OD600 and induced with 0.4 mM isopropyl-1-thio-d-galacto-
pyranoside. After 3 h, cells were collected by centrifugation, resus-
pended in ice-cold lysis buffer (150 mM NaCl, 100 mM Tris-Cl, 
pH 8, 1 mM EDTA, 1 mM -mercaptoethanol, 5 mg/ml leupeptin, 
1 mg/ml pepstatin, and 100 µM phenylmethylsulfonyl fluoride) 
with the addition of 10 µg/ml DNase and 0.25 mg/ml lysozyme, 
and sonicated on ice 12 times for 20 s, and the lysate was cleared 
by centrifugation for 30 min at 20,000 g. Protein was purified 
by affinity chromatography using StrepTrap HP columns (GE 
Healthcare) according to the manufacturer’s instructions and 
eluted in 150 mM KCl, 30 mM HEPES, pH 7.4, and 10% wt/vol 
glycerol plus 2.5 mM desthiobiotin. All purification steps were 
performed at 4°C and monitored using the ÄKTApurifier UPC 
10 fast protein liquid chromatography system (GE Healthcare). 
The eluted protein was then loaded into HiLoad 16/60 Super-
dex 200 prep grade size exclusion column (GE Healthcare), 
which was equilibrated with 150 mM KCl, 30 mM HEPES, pH 7.4, 
and 10% wt/vol glycerol, and the protein purity was confirmed 
by SDS-PAGE.
Inside-out patch recordings and data analysis
Macroscopic currents were recorded from excised patches 2–3 d 
after cRNA injection using an EPC-9 amplifier and PULSE acqui-
sition software (HEKA). Patch pipettes had resistances around 
1 MΩ after fire polishing. External (pipette) solutions contained 
(mM): 96 KCl, 1 NaCl, 1 MgCl2, 1.8 CaCl2, and 10 HEPES, pH 7.4 
(titrated with 50% KOH). Internal (bath) solutions contained 
(mM): 96 KCl, 1 NaCl, 10 HEPES, and 5 EGTA, pH 7.4. 3-s voltage 
steps were applied from a holding potential of 30 mV to a range 
of test potentials between 70 and 140 mV in 10-mV decre-
ments, followed by a depolarizing step to 40 mV to measure tail 
currents. All recordings were obtained at room temperature 
(22–24°C). Peak tail current amplitudes were measured at either 
0 mV for two electrode voltage clamp or 40 mV for patch clamp 
recordings after the decay of the capacitive transient, and tail cur-
rent–voltage curves were fitted using the Boltzmann equation 
I(V) = A1 + A2/{1 + exp[(V  V1/2)/s]}, in which A1 is the offset 
caused by holding current, A2 is the maximal tail current ampli-
tude, V is the test pulse voltage, V1/2 is the midpoint voltage of 
activation, and s is the slope factor (in mV). Because the 3-s long 
pulse was not sufficient to reach steady-state activation levels at 
less negative voltage steps, these represent isochronal activation 
curves rather than true steady-state curves. Nonetheless, they are 
likely to provide a good approximation of true V1/2 values, espe-
cially in the absence of cAMP or in the presence of relatively high 
cAMP levels (Wang et al., 2002) and have been routinely used in 
the literature because of problems with membrane breakdown 
with longer hyperpolarizations (Wainger et al., 2001; Zhou and 
Siegelbaum, 2007; Zolles et al., 2009).
The Hill equation was fitted to the cAMP dose–response data 
(Figs. 1, 3, and 7): V1/2 = Vmax/{1 + (K1/2/[cAMP])h}, where 
V1/2 is the V1/2 shift produced by a given cAMP concentration, 
Vmax is the maximal V1/2 shift produced by saturating cAMP, K1/2 
is the concentration of cAMP producing half of the maximal shift, 
and h is the Hill coefficient. In Fig. 5 F, the Hill equation was fitted 
to the TRIP8bcore peptide dose–response data. The data analysis 
and function fitting were performed in PULSE FIT (HEKA) and 
Igor Pro (WaveMetrics).
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intracellular modulatory factor (Santoro et al., 2009). 
In contrast, we found that the regulatory effect of 
TRIP8b was robustly maintained in cell-free patches 
with a TRIP8b-HCN1 fusion protein (Santoro et al., 2009). 
In our present study of the action of TRIP8b on HCN2, 
we have therefore covalently linked the N terminus 
of HCN2 to either the C terminus of TRIP8b or to GFP 
(as a control).
As shown in Fig. 1, application of cAMP to GFP-HCN2 
channels in inside-out patches produces a large, dose-
dependent depolarizing shift in the voltage depen-
dence of channel activation and increases the rate of 
channel opening, actions which are identical to those 
seen in WT HCN2 channels (Pian et al., 2006). In cell-
free patches in the absence of cAMP, TRIP8b-HCN2 
channels exhibit a similar voltage dependence and rate of 
activation compared with GFP-HCN2 channels (Fig. 1, 
A–C). However, TRIP8b-HCN2 channels show a marked 
reduction in sensitivity to cAMP compared with GFP-
HCN2 channels (Fig. 1, A–C). An examination of the 
cAMP dose–response curves for GFP-HCN2 and TRIP8b-
HCN2 demonstrates that the presence of TRIP8b 
causes a 40-fold increase in the concentration of cAMP 
required to produce a half-maximal shift in the voltage 
R E S U L T S
TRIP8b exerts opposing actions on the ability of cAMP  
to shift voltage-dependent gating and increase  
maximal current through HCN2 channels
In this study, we examined the biophysical mechanisms 
that underlie the action of TRIP8b to alter the response 
of HCN channels to cAMP by addressing two questions: 
(1) How does the binding of TRIP8b to HCN chan nels 
inhibit the effect of cAMP to shift HCN channel voltage 
gating to more positive voltages, and (2) does TRIP8b 
alter the action of cAMP to enhance the maximal 
tail current carried by HCN channels after steps to ex-
treme negative voltages? We focused on the inter action 
of TRIP8b with HCN2 because this -subunit forms 
channels that respond to cAMP with a large depolariz-
ing voltage shift and noticeable enhancement in maxi-
mal current.
In a previous study, our laboratory found that the ac-
tion of TRIP8b to antagonize the cAMP-dependent shift 
in HCN1 voltage gating observed in intact cells was 
greatly diminished upon patch excision when TRIP8b 
and HCN1 were expressed independently, perhaps be-
cause of instability of the complex and/or loss of some 
Figure 1. Effect of fusion of TRIP8b to HCN2 on re-
lationship between [cAMP] and voltage dependence 
of channel gating. (A) Currents elicited by hyperpo-
larizing voltage steps in inside-out patches from oo-
cytes expressing TRIP8b-HCN2 fusion channels or 
GFP-HCN2 channels in 0, 0.1, or 100 µM [cAMP]. 
The membrane was held at 40 mV for 0.5 s and 
then stepped for 3 s to test potentials from 70 to 
140 mV in 10-mV decrements. (B and C) Normal-
ized tail current G-V relationship for GFP-HCN2 (B) 
or TRIP8b-HCN2 (C) channels in the presence of 0, 
0.1, or 100 µM [cAMP]. Fits of Boltzmann relation 
yield the following values for V1/2 and slope with dif-
ferent [cAMP]. GFP-HCN2 0 cAMP: V1/2 = 116.0 mV, 
s = 4.98; 0.1 cAMP: V1/2 = 105.7 mV, s = 5.33; and 
100 cAMP: V1/2 = 96.9 mV, s = 4.65. TRIP8b-HCN2 
0 cAMP: V1/2 = 114.8mV, s = 4.05; 0.1 cAMP: V1/2 = 
113.3 mV, s = 4.91; and 100 cAMP: V1/2 = 104.2 
mV, s = 4.42. (D) V1/2 as a function of [cAMP] 
for GFP-HCN2, GFP-HCN2 + TRIP8b expressed as 
independent proteins, and TRIP8b-HCN2 fusion 
channels in inside-out patches. Solid lines show fits 
of Hill equation. Fits of the Hill equation yield GFP-
HCN2: Vmax = 17.3 mV, K1/2 = 0.08 µM, h = 1.43; 
GFP-HCN2 + TRIP8b: Vmax = 14.2 mV, K1/2 = 0.19 µM, 
h = 0.83; and TRIP8b-HCN2: Vmax = 11.1 mV, K1/2 = 
3.42 µM, h = 0.79. Error bars indicate SEM.
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whereas cAMP increases maximal current in GFP-HCN2 
channels by only 37 ± 9%, the nucleotide enhances max-
imal current in TRIP8b-HCN2 channels by 83 ± 9%, 
more than a twofold increase (P < 0.05; n = 10). Thus, 
TRIP8b exerts opposing actions on the two modula-
tory effects of cAMP: TRIP8b inhibits the ability of 
cAMP to shift voltage gating to more positive potentials, 
whereas it increases the action of cAMP to enhance 
maximal current.
An 81–amino acid domain in the conserved core of TRIP8b 
is both necessary and sufficient to produce the opposing 
actions of TRIP8b on cAMP-dependent modulation of HCN2
Are the two distinct actions of TRIP8b mediated by the 
same region of the molecule? We previously found that 
an 81–amino acid core region of TRIP8b, TRIP8bcore 
corresponding to residues 223–303 in TRIP8b(1a-4), is 
sufficient to fully reproduce the effect of full-length 
TRIP8b to antagonize the actions of cAMP on HCN1 
channel voltage gating, based on the action of the 
TRIP8bcore-HCN1 fusion protein in intact oocytes 
(Santoro et al., 2011). However, these experiments did 
not quantify the effect of the TRIP8b core region on 
the relation between cAMP concentration and the 
voltage shift in HCN channel gating. Moreover, these 
experiments did not examine whether the core region 
could mimic the effect of full-length TRIP8b to en-
hance the ability of cAMP to increase HCN channel 
maximal current.
We therefore next examined the effect of cAMP on 
voltage gating and maximal current of TRIP8bcore-
HCN2 fusion protein channels. We found that the rela-
tively small core region is necessary and sufficient to 
both inhibit the ability of cAMP to alter voltage gating 
dependence of channel activation (K1/2; Fig. 1 D). More-
over, there is a 40% decrease in the maximal shift in the 
V1/2 in response to saturating concentrations of cAMP 
(Vmax), a measure of ligand efficacy (Fig. 1 D).
We found a qualitatively similar inhibitory action on the 
modulatory effects of cAMP when TRIP8b is coexpressed 
with GFP-HCN2 as independent proteins (Fig. 1 D). How-
ever, similar to our previous results with HCN1 (Santoro 
et al., 2009), the quantitative extent of inhibition pro-
duced by the independent TRIP8b protein is much less 
than with the TRIP8b-HCN2 fusion. Thus, expression of 
TRIP8b with GFP-HCN2 causes only a 2.5-fold increase in 
the K1/2 for cAMP and a 20% decrease in Vmax. Our re-
sults differ slightly from those of Zolles et al. (2009), who 
found that coexpression of TRIP8b with HCN2 caused a 
somewhat larger decrease in Vmax (40%) and pro-
duced a slight decrease in the K1/2 (40%) for cAMP. 
These discrepancies may reflect small differences in re-
cording conditions or relative levels of protein expres-
sion. We also found that the Hill coefficient is reduced by 
44% by TRIP8b coexpression or fusion to HCN2 (from 
1.43 to 0.8), suggesting that TRIP8b might inhibit the 
cooperativity of cAMP binding. Neither TRIP8b coexpres-
sion or fusion to HCN2 alters the voltage dependence of 
HCN2 channel gating in the absence of cAMP, indicating 
that this regulatory subunit has minimal effect on the 
basal channel voltage gating (V1/2 values: GFP-HCN2, 
116.2 ± 0.86 mV; GFP-HCN2 + TRIP8b, 116.0 ± 0.98 
mV; and TRIP8b-HCN2, 114.7 ± 0.74 mV).
Next we asked whether TRIP8b alters the action of 
cAMP to enhance maximal HCN2 current after voltage 
steps to extreme hyperpolarized potentials. Unexpectedly, 
we found that fusion of TRIP8b to HCN2 increases the 
extent to which cAMP enhances Imax (Fig. 2). Thus, 
Figure 2. cAMP causes a larger in-
crease in maximal current with TRIP8b-
HCN2 and TRIP8bcore-HCN2 channels 
than with GFP-HCN2 channels. The 
membrane was held at 40 mV and 
then hyperpolarized to 140 mV with 
a 3-s test pulse, followed by a depolar-
izing pulse to 40 mV to measure the 
tail current. (A) Representative cur-
rents for GFP-HCN2, TRIP8b-HCN2, 
and TRIP8bcore-HCN2 channels before 
(black traces) and after (red traces) ap-
plication of saturating concentrations 
of cAMP (100 µM for GFP-HCN2 and 
1 mM for the other two channels) to 
inside-out patches. (B) Percent increase 
in maximal tail current amplitude 
in response to cAMP for GFP-HCN2, 
TRIP8b-HCN2, and TRIP8bcore-HCN2; 
error bars indicate SEM. Mean percent 
increases in maximal current ± SEM 
are as follows: GFP-HCN2: 37 ± 9% 
(n = 9); TRIP8b-HCN2: 83 ± 9% (n = 10); and TRIP8bcore-HCN2: 116 ± 18% (n = 9). Current amplitude increase with GFP-HCN2 by cAMP 
is significantly less than that seen with TRIP8b-HCN2 and TRIP8bcore-HCN2 (*, P < 0.05, ANOVA). There is no significant difference in 
current increase between the latter two constructs (P > 0.05, t test).
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actions of cAMP with TRIP8b fusion proteins are not 
the result of some nonspecific effects of the fusion per se, 
as the effects are completely dependent on the short 
internal stretch of 22 amino acids. Consistent with re-
sults using full-length TRIP8b, neither the TRIP8bInt 
nor the TRIP8bcore fusion proteins show altered volt-
age-dependent gating in the absence of cAMP (Fig. 3 B), 
further indicating that basal voltage gating is not af-
fected by this regulatory subunit.
Effects of acute application of a TRIP8bcore peptide 
to HCN2 channels
How does TRIP8b exert its opposing effects on the 
cAMP-dependent modulation of HCN2, inhibiting the 
action of cAMP to shift voltage gating while enhancing 
the action of cAMP to increase maximal current? Previ-
ous studies have suggested that channel opening 
involves a voltage-dependent activation step followed by 
a voltage-independent opening reaction. cAMP binding 
is thought to stabilize the open state of the channel, 
thereby enhancing maximal open probability and, 
thereby, maximal current (Shin et al., 2004; Chen et al., 
2005; Zhou and Siegelbaum, 2007). The relatively large 
maximal open probability of HCN2 in the absence of 
cAMP (>0.5) normally limits the extent to which cAMP 
can enhance maximal current (Zhou and Siegelbaum, 
2007). We therefore hypothesized that TRIP8b might 
enhance the ability of cAMP to increase maximal cur-
rent by depressing maximal channel open probability in 
the absence of cAMP, thereby providing a larger dynamic 
range by which cAMP can increase channel opening.
To directly address this possibility, we examined the 
effect of acute application of a soluble, purified TRIP8b 
core peptide (TRIP8b residues 223–303) to HCN2 chan-
nels in cell-free inside-out patches (using oocytes where 
TRIP8b was not coexpressed with HCN2). Consistent 
with the above hypothesis, application of 4 µM TRIP8b 
core peptide to HCN2 channels in the absence of cAMP 
causes a marked, 40%, decrease in current amplitude 
in response to a hyperpolarizing voltage step to 140 mV, 
a potential at which voltage-dependent activation is 
complete (Fig. 4 A). In contrast, the core peptide pro-
duces no detectable change in the voltage dependence 
of channel gating (Fig. 3 B). Over a range of concentra-
tions, the core peptide causes a dose-dependent reduc-
tion in HCN2 channel maximal current (in the absence 
of cAMP), resulting in a 60% decrease in current at 
40 µM, the maximum concentration of core peptide that 
was soluble (Fig. 4 B).
To determine whether the effects of TRIP8bcore on 
maximal current are specific, we examined the action 
of a mutant core peptide in which a conserved penta-
peptide sequence (EEEFE) is replaced with a charge-
reversed sequence (RRRAR; Fig. 4, C and D). In a yeast 
two-hybrid assay, we find that this mutation abolishes 
the ability of TRIP8b to bind to the HCN1 CNBD 
and facilitate the action of cAMP to increase maximal 
current (Figs. 2 and 3 A). Surprisingly, the magnitude 
of some of the effects of TRIP8bcore on the cAMP-depen-
dent modulation of HCN2 are even greater than those 
seen with full-length TRIP8b-HCN2. Thus, TRIP8bcore-
HCN2 fusion protein channels exhibit a >2,000-fold 
increase in the K1/2 for cAMP relative to HCN2 alone, 
a 50-fold larger effect than seen with the full-length 
TRIP8b-HCN2 fusion (Fig. 3 A). The TRIP8bcore-HCN2 
channels also display a decrease in Vmax with saturat-
ing cAMP (27% decrease). cAMP increased the maxi-
mal current carried by TRIP8bcore-HCN2 channels by 
116 ± 18%, slightly greater than the 83% increase in max-
imal current seen with cAMP with full-length TRIP8b 
fusion protein channels (P > 0.05; n = 9; Fig. 2). We 
next confirmed previous results obtained using HCN1 
channels in intact oocytes, that the TRIP8b core is nec-
essary for the action of full-length TRIP8b to inhibit 
the effects of cAMP on voltage gating (Santoro et al., 
2011). Thus, a fusion protein consisting of HCN2 plus 
full-length TRIP8b lacking only 22 amino acids in the 
core domain (TRIP8bInt-HCN2) generates channels 
whose response to cAMP is identical to that of HCN2 
expressed alone without TRIP8b (Fig. 3 A). These re-
sults further suggest that the alterations in the regulatory 
Figure 3. TRIP8b core domain is necessary to antagonize ac-
tion of cAMP on HCN2. (A) V1/2 as a function of [cAMP] for 
TRIP8bInt-HCN2 and TRIP8bcore-HCN2 channels in inside-out 
patches, compared with GFP-HCN2 and TRIP8b-HCN2 channels. 
Solid lines show fits of the Hill equation. Fits of the Hill equa-
tion yield TRIP8bInt-HCN2: Vmax = 18.2 mV, K1/2 = 0.08 µM, h = 
1.11; and TRIP8bcore-HCN2: Vmax = 13.3 mV, K1/2 = 190 µM, h = 
0.69. Note that TRIP8bInt, with internal deletion of 22 residues 
of the core domain, fails to alter cAMP dose–response relation. 
(B) V1/2 values of various indicated constructs in the absence of 
cAMP show no significant differences (P > 0.05, ANOVA). Error 
bars indicate SEM.
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potentials, similar to what we observe when the core 
peptide is fused to HCN2. Indeed, application of the 
core peptide rapidly antagonizes the ability of cAMP to 
shift HCN2 gating to more positive potentials (Fig. 5). 
At a concentration of 4 µM, TRIP8bcore almost fully 
abolishes the voltage shift in response to 0.1 µM cAMP 
and significantly reduces the voltage shift with 10 µM 
cAMP (Fig. 5, A–C). Importantly, the effect of cAMP 
recovers rapidly after wash-out of the peptide (Fig. 5 A), 
indicating that the binding between TRIP8b and HCN2 
is reversible. This rapid reversibility may explain the 
finding that the modulatory action of TRIP8b on HCN 
channel function is diminished after patch excision 
when TRIP8b and HCN subunits are coexpressed as in-
dependent proteins (Santoro et al., 2009, 2011). Impor-
tantly, the action of the core peptide to inhibit the 
effect of cAMP to shift HCN2 voltage gating results 
from a specific action of the peptide as it is prevented by 
the EEEFE to RRRAR mutation (Fig. 5 D).
Examination of the action of a range of cAMP con-
centrations reveals that, at a concentration of 4 µM, 
the TRIP8bcore peptide shifts the cAMP dose–response 
(Fig. 4 C). Application of this mutant peptide to HCN2 
channels has no effect on maximal current, arguing for 
a specific action dependent on the conserved core se-
quence (Fig. 4 D).
Is the effect of the core peptide to reduce maximal 
current related in any way to the action of cAMP to en-
hance maximal current? The two processes do indeed 
interact as the application of 100 µM cAMP fully reverses 
the inhibitory action of the core peptide on maximal 
current. Thus, cAMP application is able to increase max-
imal current to a level similar to that seen when cAMP is 
applied in the absence of core peptide (Fig. 4 A). As a 
result, cAMP application in the presence of core peptide 
produces a larger percentage increase in maximal cur-
rent amplitude compared with that seen when cAMP 
is applied in the absence of core peptide. This action 
therefore accounts for the increased effect of cAMP to 
enhance maximal current observed above with TRIP8b-
HCN2 or TRIP8bcore-HCN2 channels (Fig. 2).
We next asked whether acute application of the core 
peptide also inhibits the ability of cAMP to shift the volt-
age dependence of HCN2 opening to more positive 
Figure 4. Direct application of TRIP8bcore polypeptide to inside-out patches suppresses HCN2 maximal current in the absence of cAMP. 
(A) Representative experiment showing effects of TRIP8bcore polypeptide on HCN2 currents in inside-out patches elicited by a hyperpo-
larization to 140 mV, either in the absence or presence of cAMP. The current recording protocol is described in Fig. 3. The internal 
bath solution contained control solution, 4 µM TRIP8bcore with no cAMP, 4 µM TRIP8bcore plus 100 µM cAMP, or 100 µM cAMP with no 
TRIP8b. (B) Dose–response curve for the percent reduction in current amplitude at extreme negative voltages as a function of TRIP8bcore 
polypeptide concentration (in the absence of cAMP). Error bars show SEM. (C) The binding activity of the HCN1 C-linker/CNBD 
(residues 390–611) with WT and mutant TRIP8b (constant region, exons 5–16) assessed using a yeast two-hybrid assay. For TRIP8b, the 
yellow square represents the conserved core region. In TRIP8bcore-mut, the WT EEEFE core residues are substituted by RRRAR. The red 
colors denote the TPR domains. Activity was detected by transactivation of a GFP reporter gene. “+++” indicates very strong fluorescence; 
“” indicates no detectable fluorescence (see Santoro et al. [2011]). (D) Representative HCN2 currents before (black trace) and after 
(blue trace) the application of TRIP8bcore-mut polypeptide to inside-out patches. The current recording protocol is described in Fig. 3.
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curve for TRIP8b. Although these results are consistent 
with a competition of cAMP and TRIP8b for a single 
binding site, the finding that TRIP8b reduces the maxi-
mal response to saturating concentrations of cAMP is 
more consistent with an allosteric interaction, as dis-
cussed in the next section.
TRIP8b inhibits the effect of cAMP to facilitate HCN2 
voltage gating through an allosteric mechanism
To explore the mechanism by which TRIP8b alters the 
function of HCN2 channels, we examined whether the 
actions of TRIP8b are consistent with an extension of a 
six-state cyclic allosteric model previously used to de-
scribe the modulatory action of cAMP on HCN2 gating 
in the absence of TRIP8b (Fig. 6; Zhou and Siegelbaum, 
2007). According to this model, in the absence of cAMP, 
membrane hyperpolarization causes the channel to un-
dergo a voltage-dependent transition from a closed rest-
ing state (CR) to a closed active state (CA), from which the 
channel undergoes a voltage-independent conforma-
tional change to the open state (O). cAMP (A) can bind 
and unbind the CNBD in all three states, yielding three 
curve to higher agonist concentrations, causing a 70-
fold increase in the K1/2 for cAMP and a small decrease 
in Vmax (Fig. 5 E). The shift in K1/2 with 4 µM TRIP8bcore 
is intermediate between the results with TRIP8b-HCN2 
and TRIP8bcore-HCN2 fusion protein channels, suggest-
ing that the local effective concentration of TRIP8b in 
the two fusion proteins may be, respectively, lower and 
higher than 4 µM. Alternatively, the efficacy or affinity 
of the core peptide may differ from that observed with 
the two fusion protein channels.
We next explored the effect of a range of concentra-
tions of TRIP8bcore on the action of cAMP. The core 
peptide produces a dose-dependent inhibition of the 
effect of a given concentration of cAMP to shift the V1/2 
to more positive potentials (Fig. 5 F). Moreover, as the 
cAMP concentration is increased, higher concentrations 
of TRIP8bcore are required to produce a given level of 
inhibition of the cAMP response. Thus, TRIP8b and 
cAMP exert reciprocal inhibitory effects on each other’s 
action. TRIP8b shifts the dose–response curve for cAMP 
to higher concentrations, and conversely, cAMP produces 
a concentration-dependent shift in the dose–response 
Figure 5. Effects of TRIP8bcore polypeptide on 
action of cAMP on HCN2 channel voltage gat-
ing. (A) Representative experiment showing V1/2 
of HCN2 channels in inside-out patches with so-
lutions containing the indicated [cAMP] in the 
absence or presence of 4 µM TRIP8bcore polypep-
tide. Open circles indicate V1/2 in the absence of 
both cAMP and TRIP8bcore; closed circles indi-
cate V1/2 in the presence of 0.1 or 10 µM cAMP, 
with or without 4 µM TRIP8bcore polypeptide, 
as indicated. (B) Normalized G-V relationship 
for HCN2 channel tail currents in 0, 0.1, or 
10 µM cAMP. (C) Normalized G-V relationship for 
HCN2 channel tail currents in the presence of 4 
µM TRIP8bcore polypeptide plus 0, 0.1, or 10 µM 
cAMP. (D) Normalized G-V relationship for HCN2 
tail currents in the presence of 4 µM TRIP8bcore-
mut polypeptide plus 0, 0.1, or 10 µM cAMP. (E) 
Shift in V1/2 as a function of [cAMP] in the absence 
(open circles) or presence (closed circles) of 4 µM 
TRIP8bcore polypeptide. Solid lines show fits of the 
Hill equation, which yield HCN2: Vmax = 18.1 
mV, K1/2 = 0.08 µM, h = 0.86; and HCN2 plus 4 
µM TRIP8bcore: Vmax = 15.8 mV, K1/2 = 5.64 µM, 
h = 0.86. (F) Percent decrease in V1/2 produced 
by the indicated concentrations of cAMP as a func-
tion of TRIP8bcore concentration (left ordinate). 
Fits of the Hill equation (solid lines) yield 0.1 µM 
cAMP: K1/2 = 0.22 µM, h = 1.35, percent maximal 
decrease in V1/2 = 100%; 1 µM cAMP: K1/2 = 1.57 
µM, h = 1.69, percent maximal decrease in V1/2 = 
97%; 10 µM cAMP: K1/2 = 2.34 µM, h = 1.19, per-
cent maximal decrease in V1/2 = 69%; and 100 
µM cAMP: K1/2 = 3.96 µM, h = 0.74, percent maxi-
mal decrease in V1/2 = 42%. The Hill fit to the 
TRIP8b dose–response curve for HCN2 maximal current reduction from Fig. 4 B is replicated here for comparison (red dashed line, 
right ordinate). Error bars indicate SEM.
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TRIP8b must reduce cAMP binding to the open state 
more than it reduces cAMP binding to the closed state. 
Finally, as the various states are incorporated in a cyclic 
reaction scheme, cAMP binding must necessarily re-
duce the affinity of the channel for TRIP8b. We ad-
justed the parameters of the model to obtain the best fit 
to the measured relation between [cAMP] and V1/2, in 
the presence of 0–12 µM TRIP8bcore peptide (Fig. 7; see 
supplemental text for details).
The model provides a good fit to the cAMP dose– 
response curves in both the absence and presence of 
increasing concentrations of TRIP8b. In particular, the 
model reproduces the effect in which increasing con-
centrations of TRIP8b cause both a progressive shift 
in the cAMP dose–response curve to higher concentra-
tions of cAMP and a progressive decrease in the maxi-
mal response to saturating cAMP (Fig. 7). Based on the 
parameters obtained from the fit (see legend to Fig. 7), 
we infer that binding of TRIP8b produces a 70-fold de-
crease in the affinity of the closed channel for cAMP. 
Conversely, binding of cAMP produces an identical de-
crease in the affinity of the closed channel for TRIP8b. 
For the open channel, cAMP or TRIP8b binding pro-
duces an even greater 300-fold decrease in affinity for 
the antagonistic ligand. The finding that the K KTC
A
TO
A/  
ratio (9.6) is much smaller than the K KC
A
O
A/  ratio (105) 
indicates that TRIP8b binding does indeed reduce the 
corresponding agonist bound states: ACR, ACA, and AO. 
The key property of this model is that the opening transi-
tion is allosterically coupled to a conformational change 
in the CNBD that enhances the affinity of the open state 
for cAMP (dissociation constant KO
A ), relative to the af-
finity of the two closed states (identical dissociation con-
stant KC
A ). Thus, cAMP binding to the open state is 
energetically more favorable than binding to the closed 
state, causing agonist binding to shift the equilibrium 
toward the open transition by the factor K KC
A
O
A/ .  Be-
cause the voltage-independent opening reaction is ki-
netically coupled to the voltage-dependent activation 
step, the cAMP-dependent enhancement of channel 
opening both shifts the apparent voltage dependence of 
channel gating to more positive potentials and increases 
maximal open probability.
We incorporated TRIP8b (T) into this model by as-
suming it binds to the open and closed states of the 
channel, in both the cAMP-bound or unbound states. 
This results in an additional six states for the TRIP8b-
bound channel, three states with the CNBD unoccu-
pied by cAMP (TCR, TCA, and TO; Fig. 6, top face), and 
three states with the CNBD occupied by cAMP (ACRT, 
ACAT, and AOT; Fig. 6, back face). According to the 
model, TRIP8b binding may, in principle, alter the af-
finity of both the closed and open states for cAMP. Our 
finding that TRIP8b decreases Vmax implies that 
Figure 6. 12-state allosteric model for regulation of HCN2 channel opening by voltage, cAMP, and TRIP8b. The vertical and front-
back transitions of the cubic scheme represent the cAMP and TRIP8b binding reactions to the channel, respectively. The two hori-
zontal transitions are the voltage-dependent activation step reflecting voltage sensor movement, followed by a voltage-independent 
opening step. The front face of the cube is the six-state cyclic allosteric model that represents the effects of voltage and cAMP on 
channel opening in the absence of bound TRIP8b (Zhou and Siegelbaum, 2007); the top face is a six-state cyclic allosteric model 
that represents the actions of voltage and TRIP8b binding on channel opening in the absence of bound cAMP. TRIP8b and cAMP 
can both bind to the channel at the same time, as represented by the back and bottom faces of the cube. Definition of states and 
ligands: CR, unliganded closed channel with voltage sensor in the resting state; CA, unliganded closed channel with voltage sensor in 
the activated state; O, unliganded channel in the open state; A, cAMP; T, TRIP8b. Definition of parameters: KV, equilibrium constant 
for transition of closed channel transition between resting state and activated state; L, intrinsic equilibrium constant for channel 
opening; KC
A  and KO
A ,  dissociation equilibrium constants for cAMP binding to closed and open states, respectively; KC
T  and KO
T ,  
dissociation equilibrium constants of TRIP8b binding to channel in closed and open states, respectively; KTC
A  and KTO
A ,  dissociation 
equilibrium constants for cAMP binding to TRIP8b-bound channels in closed and open states, respectively; KAC
T  and KAO
T ,  dissocia-
tion equilibrium constants for TRIP8b binding to cAMP-bound channels in closed and open states, respectively.
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with a separate low-affinity binding site on the channel 
distinct from the high-affinity site responsible for the 
action of TRIP8b to antagonize the cAMP-dependent 
shift in HCN2 voltage gating. Consistent with such a dis-
sociation, we find that a point mutation in a conserved 
arginine, HCN2R591E, which profoundly disrupts the 
binding to the CNBD of both cAMP (Chen et al., 2001; 
Zhou and Siegelbaum, 2007) and TRIP8b (Han et al., 
2011), has no effect on the ability of the TRIP8b core 
polypeptide to reduce HCN2 maximal current (Fig. 8). 
Collectively, these observations strongly argue that 
TRIP8b reduces maximal current through a kinetic and 
structural mechanism that is distinct from its action to 
antagonize the effect of cAMP on HCN2 voltage gating. 
We next explore in more detail the mechanism for this 
second action of TRIP8b to suppress maximal current.
Molecular mechanism underlying the action of TRIP8b  
to reduce HCN2 channel current
TRIP8b and HCN1 have been previously found to inter-
act at two sites (Lewis et al., 2009; Han et al., 2011; 
Santoro et al., 2011). At an upstream site the core re-
gion of TRIP8b binds to the CNBD of the channel; at a 
downstream site the C-terminal TPR domain of TRIP8b 
binds the extreme C-terminal SNL tripeptide of the 
channel. Which channel domains are required for the 
action of the TRIP8b core peptide to regulate HCN2 
maximal current? We find that truncation of HCN2 at 
the N terminus of the CNBD blocks the ability of TRIP8b 
to reduce HCN2 channel current (HCN2CNBD; Fig. 8). 
In contrast, as stated above, the HCN2R591E point muta-
tion does not alter the action of 4 µM TRIP8b to reduce 
maximal HCN2 current (Fig. 8). These results suggest 
that, although a direct interaction of TRIP8b with the 
CNBD may not be required and some other previously 
unrecognized low-affinity binding site may be impor-
tant for the reduction in channel current, the presence 
of the CNBD is still essential for TRIP8b to exert its ef-
fect to reduce maximal current amplitude (either by 
contributing to the integrity of the low affinity binding 
site or by acting as an effector domain).
If the action of TRIP8b to reduce HCN2 maximal 
channel current does not depend directly on its interac-
tion with the CNBD, how does cAMP antagonize this ac-
tion? A previous study has suggested that cAMP binding 
enhances HCN channel opening by relieving an inhibi-
tory action of the CNBD on channel gating (Wainger 
et al., 2001). At a structural level, cAMP is thought to act 
by promoting assembly of the four CNBDs in a channel 
into a tetrameric gating ring (Zagotta et al., 2003). We thus 
hypothesized that the inhibitory action of TRIP8b on 
channel current is only manifest when the gating ring is 
disassembled, that is, in the absence of cAMP. To test this 
hypothesis, we took advantage of a triple point mutation 
our laboratory previously identified in the first (A) helix 
of the cytoplasmic C-linker region of the channel, which 
affinity of the open state for cAMP to a greater extent 
than it reduces affinity of the closed state for cAMP. 
Moreover, this accounts for the action of TRIP8b to in-
hibit the efficacy with which cAMP shifts the voltage de-
pendence of channel gating, resulting in the decrease 
in Vmax.
In principle, the model could also account for our ob-
servation that TRIP8b reduces HCN2 maximal current in 
the absence of cAMP (as shown in Fig. 4), if TRIP8b were 
to bind to the cAMP-free closed state more tightly than 
it were to bind to the cAMP-free open state. However, the 
best fit of the model yields nearly identical values for KC
T  
(0.089 ± 0.027 µM) and KO
T  (0.064 ± 0.010 µM). A sec-
ond discrepancy is seen when we independently adjusted 
KC
T  and KO
T  to fit the observed reduction in Imax (Fig. 4 B). 
In this case, the model predicts that TRIP8b should pro-
duce a 3-mV shift in the voltage dependence of gating 
in the absence of cAMP, an effect we do not observe 
(Fig. 3 B). Moreover the estimates of KC
T  and KO
T  obtained 
from the fits in the absence of cAMP are 4- to 30-fold 
larger (KC
T  = 0.34 µM; KO
T  = 1.90 µM) than those ob-
tained when we fit the relation between TRIP8b core 
polypeptide concentration and the magnitude of the 
shift in voltage gating with cAMP (compare Fig. 4 B  
with Fig. 5 F; see Model fitting subsection of Materials 
and methods).
The above discrepancies suggest that the effects of 
TRIP8b to inhibit maximal current amplitude in the ab-
sence of cAMP are mediated through an interaction 
Figure 7. V1/2 as a function of [cAMP] and [TRIP8bcore] poly-
peptide, fitted by the 12-state allosteric model. The TRIP8bcore 
polypeptide concentrations are indicated. The parameters of 
the front face of the model (corresponding to the six-state cyclic 
model) are adopted from Zhou and Siegelbaum (2007): L = 0.43, 
s = 4.4, KC
A  = 0.844 µM, KO
A  = 0.008 µM. The best fit of the model 
yields the following values for the other parameters: KC
T  = 0.089 ± 
0.027 µM, KO
T  = 0.064 ± 0.010 µM, KTC
A  = 33.58 ± 8.18 µM, 
KTO
A  = 3.53 ± 1.33 µM. KAC
T  and KAO
T  are then derived from the 
other parameters: KAC
T  = K K KTC
A
C
T
C
A⋅ /  = 3.54 µM and KAO
T  = 
K K KTO
A
O
T
O
A⋅ /  = 28.24 µM. Error bars show SEM. See supplemen-
tal text for further details.
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2007). In this model, cAMP facilitates channel open-
ing by binding more tightly to the open than to the 
closed state of the channel. In the expanded 12-state 
model, TRIP8b exerts an allosteric action that reduces 
the affinity of both the closed and open states of the 
channel for cAMP. Conversely, cAMP binding pro-
duces an allosteric effect to reduce the affinity of the 
closed and open channel for TRIP8b. Because TRIP8b 
also reduces Vmax, its binding must reduce the cAMP 
affinity of the open state to a greater extent than it re-
duces the cAMP affinity of the closed state, a predic-
tion which was confirmed by our detailed modeling 
results. In contrast, unlike cAMP, which binds much 
more favorably to the open state than the closed state, 
TRIP8b binds with similar affinity to the open and 
closed states of the channel.
A recent biochemical study focused on the nature of 
the interaction between TRIP8b and HCN1 at the up-
stream interaction site, using a channel in which the 
C-terminal SNL tripeptide was deleted to prevent the 
interaction at the downstream site (Han et al., 2011). 
Under these conditions the binding between TRIP8b 
and HCN1 is reduced by cAMP in a concentration-
dependent manner. Moreover the binding of TRIP8b 
to the HCN1SNL truncation mutant is abolished when 
a highly conserved arginine residue in the CNBD, 
which interacts with the cyclized phosphate of cAMP, 
is mutated to glutamate (R538E in HCN1 and R591E 
in HCN2). This led Han et al. (2011) to conclude that 
the core region of TRIP8b may directly bind to this 
conserved arginine, thereby competing with cAMP for 
the CNBD.
connects the S6 transmembrane segment to the CNBD. 
We found that this mutation promotes gating ring assem-
bly in the absence of cAMP (Zhou et al., 2004). We there-
fore predicted that this mutation should also block the 
action of TRIP8b to reduce channel current. As shown in 
Fig. 8 (HCN2FPN), the triple point mutation does indeed 
block the effect of TRIP8b to inhibit HCN2 maximal cur-
rent, supporting the hypothesis outlined above.
DISCUSSION
In this study, we report that TRIP8b exerts multiple effects 
on HCN2 channel function. The auxiliary subunit shifts 
the relation between V1/2 and [cAMP] to higher concen-
trations, decreasing the sensitivity of the channel to cAMP. 
TRIP8b also decreases the maximal voltage shift in re-
sponse to a saturating concentration of cAMP (Vmax), re-
flecting a reduction in cAMP efficacy. Finally, in the 
absence of cAMP, TRIP8b inhibits the maximal current 
through the channel. Because this latter effect is antago-
nized by cAMP, TRIP8b enhances the action of cAMP to 
increase maximal current through the channel.
An allosteric mechanism accounts for the action  
of TRIP8b to inhibit the effect of cAMP to shift  
the voltage dependence of HCN2 channel opening
The effect of TRIP8b to inhibit the cAMP-dependent 
modulation of HCN2 voltage gating can be accounted 
for by an expansion of a six-state allosteric model that 
has been previously used to describe the dual actions 
of voltage and cAMP to promote HCN2 channel open-
ing in the absence of TRIP8b (Zhou and Siegelbaum, 
Figure 8. Importance of C-terminal regions of HCN2 for the ability of TRIP8b to reduce maximal current. (A) Representative currents 
through HCN2 WT and mutant channels before (black traces) and after (blue traces) the application of 4 µM TRIP8bcore polypeptide to 
inside-out patches (no cAMP present). HCN2CNBD, truncation after residue V526 removing entire CNBD and all downstream residues; 
HCN2R591E, point mutation of conserved arginine in CNBD required for high-affinity cAMP binding; HCN2FPN, triple point mutation 
substituting FPN sequence for residues QEK in A helix of C-linker (residues 450–452 in HCN2). The recording protocol is described 
in Fig. 2. (B) Percent reduction in maximal tail current amplitude for HCN2 WT and mutant channels in response to 4 µM TRIP8bcore 
polypeptide. Error bars indicate SEM. Mean percent reductions ± SEM are as follows: HCN2, 43 ± 4% (n = 9); HCN2CNBD, 1.6 ± 2% (n = 3); 
HCN2R591E, 48 ± 9% (n = 3); and HCN2FPN, 1 ± 2% (n = 3).
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TRIP8b inhibits maximal current through HCN2 channels 
through a second action
What is the relation between the action of TRIP8b to 
reduce maximal Ih in the absence of cAMP and the ac-
tion of TRIP8b to decrease the affinity of the CNBD for 
cAMP? As discussed in the Results, although in princi-
ple the 12-state allosteric model can account for both of 
these actions through TRIP8b binding more tightly to 
the closed than open state of the channel, this single 
mode of action is not consistent with our experimental 
and modeling results. Rather, the reduction in maximal 
macroscopic current appears to be caused by a second, 
low-affinity action of TRIP8b to reduce maximal chan-
nel current. Such an effect could result from a reduc-
tion in channel open probability or from a reduction in 
single channel conductance.
One important caveat with our modeling results is 
that the 12-state allosteric reaction scheme does not take 
into account the tetrameric nature of the channel and 
its interaction with cAMP (Ulens and Siegelbaum, 2003) 
and TRIP8b (Bankston et al., 2012). Furthermore, a re-
cent study suggests that the gating of HCN2 channels is 
much more complex than our model, involving a pro-
found cooperative interaction (Kusch et al., 2012). Al-
though our initial attempts to fit a model with multiple 
equivalent cAMP and TRIP8b binding sites did not yield 
a significant improvement in our ability to describe the 
two effects of TRIP8b through a single mechanistic ac-
tion, some more complex model with nonequivalent 
binding sites (Ulens and Siegelbaum, 2003; Kusch et al., 
2012) may prove adequate to explain our results based 
on a single underlying action of TRIP8b.
If TRIP8b does indeed exert separate high- and low-
affinity actions at two distinct binding sites that, respec-
tively, antagonize the action of cAMP on voltage gating 
and reduce maximal current in the absence of cAMP, 
where are these sites located? One possibility is that 
TRIP8b binds to two separate sites within the CNBD. 
However it is unclear as to how the relatively compact 
CNBD could accommodate multiple TRIP8b proteins. 
Also, any interaction of TRIP8b with a second CNBD-
binding site that reduces maximal current must be 
impervious to the R591E mutation, which disrupts 
high-affinity binding of TRIP8b to the CNBD (Fig. 9; 
Han et al., 2011). Rather, we favor a model in which the 
core region of TRIP8b binds to two separate sites on the 
channel, a high-affinity site on the CNBD that allosteri-
cally reduces cAMP binding and a low-affinity site located 
elsewhere in the channel that reduces maximal current, 
perhaps by decreasing apparent single channel conduc-
tance. As we previously failed to detect an interaction 
between the TRIP8b core peptide and the C-terminal 
downstream HCN1 binding site using a yeast two-hybrid–
based assay (Santoro et al., 2011), this second site is likely 
to be located either within the C-linker or within the 
channel’s intracellular loops.
However, the finding that TRIP8b reduces the maxi-
mal voltage shift with saturating concentrations of 
cAMP (Zolles et al., 2009) indicates that the auxiliary 
subunit does not directly compete with cAMP for the 
channel but acts through an allosteric mechanism to 
decrease the affinity of the CNBD for ligand. More-
over, several additional lines of evidence make it un-
likely that TRIP8b directly interacts with the binding 
domain arginine (R591 in HCN2). First, the crystal 
structure of the HCN2 CNBD with cAMP bound shows 
that the arginine is embedded in the binding pocket 
and surrounded by the CNBD -roll (Zagotta et al., 
2003). Although cAMP or cGMP are small enough to 
enter the pocket and interact with the arginine, it is 
unclear how the internal core domain of TRIP8b 
would have ready access to this site. Second, we find 
that the binding of TRIP8b to HCN1 is not altered 
when the corresponding arginine (R538) is substi-
tuted with alanine (HCN1 R538A), although we con-
firmed that the R538E mutation does weaken the 
binding of TRIP8b to the channel (Fig. 9). These re-
sults can be reconciled if the conserved arginine of the 
CNBD does not directly interact with TRIP8b, but 
rather its substitution by glutamate results in a local 
disruption of the CNBD, thereby weakening the bind-
ing of TRIP8b. We further hypothesize that this local 
structural change in the CNBD may not occur with 
the less disruptive alanine substitution. More detailed 
structural studies, including x-ray crystallography, are 
needed to identify the precise location of the TRIP8b 
binding site.
Figure 9. The effect of mutations in the HCN1 key CNBD residue 
R538 on TRIP8b binding. Western blot analysis shows binding of 
HCN1, HCN1R538A, and HCN1R538E mutants to WT TRIP8b(1b-2) 
assessed by coimmunoprecipitation from Xenopus oocyte extracts 
coinjected with TRIP8b and HCN1 cRNA. The top row shows the 
HCN1 input signal using an HCN1 antibody. The middle row 
shows the TRIP8b input signal using an anti-TRIP8b antibody. The 
bottom row shows the amount of HCN1 protein coimmunoprecipi-
tated with the TRIP8b antibody (Western blot probed using HCN1 
antibody). Note that exposure times are directly comparable along 
each row but not down each column. Individual bands have been 
cut from intact gel pictures and aligned to allow direct comparison 
of intensities for WT and mutant constructs.
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